DIA
ALNY icon

Denver Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Denver Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,490
Closed -$517K – 466
2015
Q4 		$517K Buy
5,490
+310
+6% +$28.7K 0.02% 346
2015
Q3 		$416K Buy
5,180
+321
+7% +$35.7K 0.02% 364
2015
Q2 		$582K Sell
4,859
-14,929
-75% -$1.78M 0.02% 351
2015
Q1 		$2.07M Sell
19,788
-17,688
-47% -$1.79M 0.07% 271
2014
Q4 		$3.63M Buy
37,476
+313
+0.8% +$29K 0.12% 193
2014
Q3 		$2.9M Sell
37,163
-554
-1% -$35.7K 0.1% 225
2014
Q2 		$2.38M Sell
37,717
-35,876
-49% -$2.13M 0.07% 268
2014
Q1 		$4.94M Buy
73,593
+19,484
+36% +$1.51M 0.15% 185
2013
Q4 		$3.48K Sell
54,109
-56,284
-51% -$3.36M 0.1% 236
2013
Q3 		$7.07M Buy
110,393
+40,900
+59% +$2.04M 0.15% 190
2013
Q2 		$2.15M Buy
+69,493
New +$1.85M 0.05% 315

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Denver Investment Advisors's ALNY Position: Q1 2016 in Review

Denver Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2016, closing a stake of 5,490 shares — an estimated $517K sold.

Denver Investment Advisors first reported a position in ALNY in Q2 2013 and held it in 11 quarters. The position peaked at $7.07M in Q3 2013. 254 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

  • Denver Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Denver Investment Advisors sold 5,490 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $517K.
  • Denver Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Denver Investment Advisors's Alnylam Pharmaceuticals position peaked at $7.07M in Q3 2013.
  • 254 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on Denver Investment Advisors's 13F filing for Q1 2016, filed 12 May 2016.